A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion (TEMPO-2)

Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Thrombolysis With Low Dose Tenecteplase (TNK-tPA) Versus Standard of Care in Minor Ischemic Stroke With Proven Acute Symptomatic Occlusion

This trial will enroll patients that have been diagnosed with a transient ischemic attack (TIA) or minor stroke that has occurred within the past 12 hours. Anyone diagnosed with a minor stroke faces the possibility of long-term disability and even death, regardless of treatment. Stroke symptoms such as weakness, difficulty speaking and paralysis may improve or worsen over the hours or days immediately following a stroke. TEMPO-2 is a minor stroke trial for patients presenting within 12 hours of their symptom onset. Patients will be randomized to TNK-tPA or standard of care. In the intervention group TNK-tPA is given as a single, intravenous bolus (0.25mg/Kg) immediately upon randomization. Maximum dose 50mg. The control group will receive antiplatelet agent(s) as decided by the treating physician. Antiplatelet agent(s) choice will be at the treating physician's discretion.

TEMPO-2 Coordinating Centre is located in Calgary, AB, Canada. There will be approximately 50 sites participating worldwide.

Dr. Shelagh Coutts is the Principal Investigator.

Study Overview

• Status: Active, not recruiting
• Conditions: Stroke, Acute
• Intervention / Treatment: Drug: Tenecteplase; Drug: Antiplatelet treatment

Detailed Description

TEMPO2 is an multicentre, prospective randomized open label, blinded-endpoint (PROBE) controlled trial of thrombolysis with low dose Tenecteplase (TNK-tPA) versus standard of care. A total of 1274 patients will be enrolled, at approximately 50 sites worldwide.

TEMPO-2 will enroll patients within a 12 hour time window with a NIHSS score of <6 and an ASPECTS >7. All patients will be evaluated clinically and then undergo brain imaging using CT followed immediately by a CT angiogram. Patients must have an intracranial occlusion on CTA or CTP.

Randomization will be 1:1 to TNK-tPA (experimental) or standard of care antiplatelet agents (control).

Experimental: TNK-tPA (0.25mg/kg) given as a single, intravenous bolus immediately upon randomization. Experimental treatment will be administered as a single intravenous bolus over 1-2 minutes.

Control: Patients will be treated with standard of care based antiplatelet treatment - choice at the discretion of the investigator. Low dose aspirin (single agent) will be the choice of most physicians, some will chose to use the combination of aspirin and clopidogrel. The local investigator to chose which antithrombotic regime should be used

All patients will be treated within 90 minutes of the first slice of the baseline CT. Patients will undergo a study CT angiogram of the intracranial circulation between 4-8 hours after treatment to determine whether the occluded artery has recanalized or not. In sites where MRI/MRA is routinely used this can be substituted for CT/CTA. Any patient who has neurological worsening should have standard of care brain imaging completed to rule out intracranial hemorrhage.

All patients will have standard of care medical management on an acute stroke unit and undergo follow-up imaging at 24 hours with CT or MR. Use of MR will be encouraged.

Patients will be assessed at 24 hours and at Days 5 and 90. The Day 90 Outcomes will be performed by a blinded assessor.

• Study Type: Interventional
• Enrollment (Estimated): 1274
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Shelagh B Coutts, MD; Phone Number: 403-944-1581; Email: scoutts@ucalgary.ca
• Study Contact Backup: Name: Carol C Kenney, RN, CCRP; Phone Number: 403-944-4286; Email: Tempo2@ucalgary.ca

Study Locations

• Australia
  • Australian Capital Territory
    • Canberra, Australian Capital Territory, Australia
      • Calvary Public Hospital Bruce
  • New South Wales
    • Newcastle, New South Wales, Australia
      • John Hunter Hospital
  • Queensland
    • Gold Coast, Queensland, Australia
      • Gold Coast University Hospital
  • South Australia
    • Adelaide, South Australia, Australia
      • Royal Adelaide Hospital
  • Victoria
    • Box Hill, Victoria, Australia
      • Box Hill Hospital
    • Melbourne, Victoria, Australia
      • Royal Melbourne Hospital
  • Western Australia
    • Murdoch, Western Australia, Australia
      • Fiona Stanley Hospital
• Austria
  • Vienna, Austria
    • Medical University of Vienna (Coordinating Centre)
  • Vienna, Austria
    • St. John's of God Hospital Vienna
• Brazil
  • Botucatu, Brazil
    • Hospital de Clínicas de Botucatu
  • Brasília, Brazil
    • Instituto Hospital de Base do Distrito Federal
  • Campo Grande, Brazil
    • Hospital Universitario Maria Aparecida Pedrossian
  • Celso Ramos, Brazil
    • Hospital Celso Ramos Florianopolos
  • Fortaleza, Brazil
    • Hospital Geral de Fortaleza
  • Joinville, Brazil
    • Clinica Neurologica e Neurocirurgica de Joinville Ltda
  • Porto Alegre, Brazil
    • Santa Casa de Porto Alegre
  • Porto Alegre, Brazil
    • Porto Alegre Hospital
  • Ribeirão Preto, Brazil
    • Hospital de Clínicas de Ribeirão Preto
  • Rio De Janeiro, Brazil
    • Américas Medical City
  • São Paulo, Brazil
    • Irmandade Da Santa Casa De Misericordia De Sao Paulo
  • São Paulo, Brazil
    • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
  • São Paulo, Brazil
    • Hospital São Paulo UNIFESP
  • Vitória, Brazil
    • Hospital Estadual Central
• Canada
  • Alberta
    • Calgary, Alberta, Canada, T2N 2T9
      • University of Calgary/Foothills Medical Centre
    • Edmonton, Alberta, Canada
      • University of Alberta
  • B.C.
    • New Westminster, B.C., Canada, V3L 3W7
      • Royal Columbian Hospital
  • British Columbia
    • Vancouver, British Columbia, Canada
      • Vancouver General Hospital
    • Victoria, British Columbia, Canada
      • Victoria General Hospital
  • Ontario
    • Hamilton, Ontario, Canada
      • Hamilton Health Sciences Centre
    • Kingston, Ontario, Canada
      • Kingston General Hospital
    • London, Ontario, Canada
      • London Health Sciences Centre
    • Ottawa, Ontario, Canada
      • Ottawa General Hospital
    • Toronto, Ontario, Canada
      • St. Michael's Hospital
    • Toronto, Ontario, Canada
      • Sunnybrook Health Sciences Centre
    • Toronto, Ontario, Canada
      • Toronto Western
  • Quebec
    • Montreal, Quebec, Canada
      • McGill University
    • Quebec City, Quebec, Canada
      • CHU de Quebec-Universite Laval
  • Saskatchewan
    • Saskatoon, Saskatchewan, Canada
      • University of Saskatchewan/ Royal University Hospital
• Finland
  • Helsinki, Finland
    • University Central Hospital HUCH
• Ireland
  • Leinster
    • Dublin, Leinster, Ireland
      • Beaumont Hospital
    • Dublin, Leinster, Ireland
      • Mater Misericordiae University Hospital Dublin
• New Zealand
  • Christchurch, New Zealand
    • Christchurch Hospital
• Singapore
  • Singapore, Singapore
    • Singapore General Hospital
  • Singapore, Singapore
    • National Neuroscience Institute Tan Tock Seng Hospital
• Spain
  • A Coruña, Spain
    • Complejo Jospitalario Universitario A Coruna
  • Barcelona, Spain
    • Vall d'Hebron Institut de Recerca (VHIR)
  • Barcelona, Spain
    • Vall d'Hebron Institut de Recerca
  • Girona, Spain
    • Hospital Universitari Doctor Josep Trueta
  • Valladolid, Spain
    • Clinc University Hospital Valladolid
• United Kingdom
  • Birmingham, United Kingdom
    • Queen Elizabeth Hospital
  • Cambridge, United Kingdom
    • Addenbrooke Hospital
  • London, United Kingdom
    • Kings College Hospital
  • London, United Kingdom
    • Charring Cross Hospital
  • Nottingham, United Kingdom
    • Nottingham University Hospital
  • Oxford, United Kingdom
    • John Radcliffe Hospital
  • England
    • London, England, United Kingdom
      • Countess of Chester
    • London, England, United Kingdom
      • St George's University Hospitals NHS Foundation Trust
    • London, England, United Kingdom
      • Stoke University of North Midlands
    • London, England, United Kingdom
      • University College London Hospital
  • Northern Ireland
    • Belfast, Northern Ireland, United Kingdom
      • Royal Victoria Hospital
  • Scotland
    • Glasgow, Scotland, United Kingdom
      • Queen Elizabeth University Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Acute ischemic stroke in an adult patient (18 years of age or older)
2. Onset (last-seen-well) time to treatment time ≤ 12 hours.
3. TIA or minor stroke defined as a baseline NIHSS ≤ 5 at the time of randomization. Patients do not have to have persistent demonstrable neurological deficit on physical neurological examination.
4. Any acute intracranial occlusion or near occlusion (TICI 0 or 1) (MCA, ACA, PCA, VB territories) defined by non-invasive acute imaging (CT angiography or MR angiography) that is neurologically relevant to the presenting symptoms and signs. Multiphase CTA or CT perfusion are required for this study. An acute occlusion is defined as TICI 0 or TICI 1 flow.1 Practically this can include a small amount of forward flow in the presence of a near occlusion AND, Delayed washout of contrast with pial vessels on multiphase CTA in a region of brain concordant with clinical symptoms and signs OR, Any area of focal perfusion abnormality identified using CT or MR perfusion - e.g. transit delay (TTP, MTT or T Max), in a region of brain concordant with clinical symptoms and signs.
5. Pre-stroke independent functional status - structured mRS ≤2.
6. Informed consent from the patient or surrogate.
7. Patients can be treated within 90 minutes of the first slice of CT or MRI. Scans can be repeated to meet this requirement; if there is no change neurologically then only a CT head need be repeated for assessment of extent and depth of ischemia.

Exclusion Criteria:

1. Hyperdensity on NCCT consistent with intracranial hemorrhage.
2. Large acute stroke ASPECTS < 7 visible on baseline CT scan.
3. Core of established infarction. No large area (estimated > 10 cc) of grey matter hypodensity at a similar density to white matter or in the judgment of the enrolling neurologist is consistent with a subacute ischemic stroke > 12 hours of age.
4. Clinical history, past imaging or clinical judgment suggest that that intracranial occlusion is chronic.
5. Patient has a severe or fatal or disabling illness that will prevent improvement or follow-up or such that the treatment would not likely benefit the patient.
6. Pregnancy
7. Planned thrombolysis with IV tPA or endovascular thrombolysis/thrombectomy treatment.
8. In-hospital stroke unless these patients are at their baseline prior to their stroke. E.g. a patient who had a stroke during a diagnostic coronary angiogram.

9. Commonly accepted exclusions for medical thrombolytic treatment. These are commonly relative contraindications (i.e. the final decision is at the discretion of the treating physician) but for the purposes of TEMPO-2 include the following:

   • International normalized ratio > 1.7 or known full anticoagulation with use of any standard or direct oral anticoagulant therapy with full anticoagulant dosing. [DVT prophylaxis dosing shall not prohibit enrolment]. For low molecular weight heparins (LMWH) more than 48 hours off drug will be considered sufficient to allow trial enrollment. For direct oral anticoagulants; in patients with normal renal function more than 48 hours off drug will be considered sufficient to allow trial enrollment. Patients on direct oral anticoagulants who have any degree of renal impairment should not be enrolled in the trial unless they have not taken a dose of the drug in the last 5 days. Dual antiplatelet therapy does not prohibit enrolment.
   • Dual antiplatelet therapy does not prohibit enrolment. [For patients who are known not to be taking anticoagulant therapy it is not necessary to wait for coagulation lab results (e.g. PT, PTT) prior to treatment]
   • Patients who have been acutely treated with GP2b3a inhibitors.
   • Arterial puncture at a non-compressible site in the previous seven days
   • Clinical stroke or serious head or spinal trauma in the preceding three months that would normally preclude use of a thrombolytic agent.
   • History of intracranial hemorrhage, subarachnoid hemorrhage or other brain hemorrhage that would normally preclude use of a thrombolytic agent.
   • Major surgery within the last 3 months at a bodily site where bleeding could result in serious harm or death.
   • Known platelet count below 100,000 per cubic millimeter. Treatment should not be delayed to wait for platelet count unless thrombocytopenia is known or suspected.
   • Gastrointestinal or genitourinary bleeding within the past 3 months that is unresolved or associated with persisting anemia such that thrombolytic treatment of any kind would result in serious bleeding or death.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Tenecteplase (tNK); Experimental: TNK-tPA (0.25mg/kg) given as a single, intravenous bolus immediately upon randomization. Experimental treatment will be administered as a single intravenous bolus over 1-2 minutes as per the standard manufacturers' instructions for use. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, has a longer half-life, is more fibrin specific, produces less systemic depletion of circulating fibrinogen, and is more resistant to plasminogen activator inhibitor than alteplase.	Drug: Tenecteplase; TNK will be administered as a single intravenous bolus over 1-2 minutes within 90 minutes of the CT scan.; Other Names: TNK-tPA
Active Comparator: Control (Antiplatelet Agents); Control: Patients will be treated with standard of care based antiplatelet treatment - choice at the discretion of the investigator. Low dose aspirin (single agent) will be the choice of most physicians, some will chose to use the combination of aspirin and clopidogrel. As this is a multi-centre, international trial where local practices will vary, rather than mandating a specific antiplatelet agent, we will allow the local investigator to chose which antithrombotic regime should be used. Standard of care medication(s) should be given immediately upon randomization.	Drug: Antiplatelet treatment; Low dose aspirin (single agent) will be the choice of most physicians, some Investigators will chose to use the combination of aspirin and clopidogrel.; Other Names: ASA, Clopidogrel

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Modified Rankin Scale (mRS)	Analysis will be a responder analysis where return to baseline level of neurological functioning is defined as follows: If pre-morbid mRS is 0-1 then mRS 0-1 at 90 days is a good outcome. If pre-morbid mRS is 2 then mRS 0-2 is a good outcome. Pre-morbid mRS is assessed using the structured mRS prior to randomization. Outcomes will be assessed by an individual blinded to the treatment assignment. The 90day mRS will be rated using the structured mRS questionnaire . The 90 day mRS will be completed in person where possible and by telephone otherwise. The structured questionnaire has been showed to improve reliability in assessing the mRS both in person and by telephone.	90 Days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Major Bleeding	1) Proportion of patients with major bleeding: This will include an analysis of symptomatic intracranial hemorrhage alone and then combined with major extracranial hemorrhage. This is the main safety outcome.	90 Days

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Complete or partial recanalization	Recanalization will be assessed by the central core-imaging lab blinded to all clinical information- TICI2b-3.	4-8 hours post treatment
Lawton Instrumental Activities of Daily Living Scale (IADL)	This scale will be used at the Day 90 follow-up visit.	90 Days
Quality of life measured on EuroQol38	This scale will be used at the Day 90 follow-up visit.	90 Days

Collaborators and Investigators

• Sponsor: University of Calgary
• Investigators: Study Director: Michael D Hill, MD, University of Calgary

Publications and helpful links

General Publications

• Logallo N, Kvistad CE, Thomassen L. Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke. CNS Drugs. 2015;29(10):811-8. doi: 10.1007/s40263-015-0280-9.
• Coutts SB, Dubuc V, Mandzia J, Kenney C, Demchuk AM, Smith EE, Subramaniam S, Goyal M, Patil S, Menon BK, Barber PA, Dowlatshahi D, Field T, Asdaghi N, Camden MC, Hill MD; TEMPO-1 Investigators. Tenecteplase-tissue-type plasminogen activator evaluation for minor ischemic stroke with proven occlusion. Stroke. 2015 Mar;46(3):769-74. doi: 10.1161/STROKEAHA.114.008504. Epub 2015 Feb 12.

Helpful Links

• TEMPO-2 website

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2015
• Primary Completion (Actual): January 19, 2024
• Study Completion (Estimated): April 10, 2024

Study Registration Dates

• First Submitted: March 20, 2015
• First Submitted That Met QC Criteria: March 24, 2015
• First Posted (Estimated): March 25, 2015

Study Record Updates

• Last Update Posted (Actual): March 19, 2024
• Last Update Submitted That Met QC Criteria: March 16, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: Minor Ischemic Stroke
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Stroke; Ischemic Stroke; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Fibrinolytic Agents; Fibrin Modulating Agents; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Purinergic P2 Receptor Antagonists; Purinergic Antagonists; Purinergic Agents; Clopidogrel; Tenecteplase
• Other Study ID Numbers: Version 3.3 , Mar 24,2017

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Overall data will be shared once the trial has been closed and data analysed. No individual participant data will be available.